Request | Notes | Status |
---|---|---|
Update the Influenza TUAG for this assay. | Outstanding CT request since 2014. Also answer questions for Kathleen |
Outstanding IS term requests from 2014 and from the Influenza TAUG require re-model of Hemagglutination Inhibition Assay Data. Note the below example describe a use-case of prophylactic seasonal influenza vaccine study conducted in healthy subjects. "The seasonal influenza (flu) vaccine is designed to protect against the three or four influenza viruses research indicates are most likely to spread and cause illness among people during the upcoming flu season. Flu viruses are constantly changing, so the vaccine composition is reviewed each year and updated as needed based on which influenza viruses are making people sick, the extent to which those viruses are spreading, and how well the previous season’s vaccine protects against those viruses." - CDC. Therefore flu vaccine creation is somewhat of an educated guess and annual prediction. Healthy subjects are normally recruited and vaccinated to test for the production of anti-influenza antibodies and other protective immune responses. |
The OI example below shows how to represent two strains of Influenza virus, Influenza B virus (B/Acre/117700/2012) and Influenza A/Michigan/45/2015, at various taxonomic and non-taxonomic levels.
|
The IS example below shows how to represent data collected from running the Hemagglutination Inhibition Assay on Influenza A and B viruses. NHOIDs generated from the OI domain above are used in the IS dataset below to show that the following tests are performed against the two specific flu A and B strains. We are assessing whether or not the antibody would prevent influenza-driven Hemagglutination process. Note the OI dataset and NHOID are used to describe and identify fully the taxonomic classification and information about the two flu strains - so such details do not have to appear elsewhere in the IS dataset.
|
Questions and Concerns:
The use-case describes a seasonal influenza vaccine study conducted in healthy subjects, this means none of the subjects is presumably naturally infected by the influenza viral strains of interest in the study.
Consensus: |
|
---|---|
Reasons: | Prophetical vaccine studies run immunogenicity tests against "known reference microbial strains" hence this is the correct use of OI and NHOID. This approach also liberates the ISBDAGNT variable from having to represent and control sub-strain level taxonomic information. |
Other Comments: | The variable ISBDAGNT is supported by two codelists: MIROORG and ISBDAGT. The MB/IS team will NOT create controlled terminology for sub-strain level microbial terms for either codelist, such as Influenza A/Michigan/45/2015, Sars-Cov-2 Omicron Variant B.1.1.529, or Escherichia coli O157:H7 str. 2009EL1449. ISBDAGNT is used to describe/identify the microorganism in the most "basic" term and the antigenic target of the antibody (e.g.. HIV-1 GP160, Sars-CoV-2 S Protein). This variable should NOT contain detailed taxonomic information of the bug, which should be mapped to OI. |